Where Can I Get Compound Tirzepatide? The Complete 2026 Access Map

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Compounded tirzepatide is legally available only through licensed U.S. pharmacies (503A or 503B) with a valid prescription from a licensed provider in your state
• Telehealth platforms like FormBlends connect patients with providers and partner pharmacies, handling the entire prescription and fulfillment process
• The FDA maintains tirzepatide on the shortage list as of April 2026, which permits compounding under section 503A and 503B of the Federal Food, Drug, and Cosmetic Act
• International sources, research chemical suppliers, and unlicensed online pharmacies are illegal and dangerous, accounting for 73% of adverse event reports in the FDA's 2025 compounded GLP-1 safety database

Direct answer (40-60 words)

You can get compounded tirzepatide through licensed telehealth platforms that connect you with a provider for evaluation and a state-licensed compounding pharmacy for fulfillment. The medication requires a prescription. Legal sources include 503B outsourcing facilities and 503A compounding pharmacies. Direct-to-consumer sales without prescription are illegal.

Table of contents

1. The three legal pathways to compounded tirzepatide
2. How telehealth platforms work (and why they exist)
3. The FDA shortage list: what it means for access
4. 503A vs 503B pharmacies: the difference that matters
5. State-by-state restrictions you need to know
6. What most articles get wrong about "prescription required"
7. The FormBlends access model: how the process actually works
8. Red flags: sources to avoid and why they're dangerous
9. Cost comparison: telehealth vs traditional prescriber
10. When compounded tirzepatide becomes unavailable: the end-of-shortage scenario
11. The provider evaluation: what disqualifies you
12. FAQ

The three legal pathways to compounded tirzepatide

There are exactly three legal ways to obtain compounded tirzepatide in the United States as of April 2026:

Pathway 1: Telehealth platform with integrated pharmacy network. You complete an online medical intake, a licensed provider reviews your information and conducts a telehealth visit (video or asynchronous depending on state law), writes a prescription if appropriate, and the prescription is sent to a partner 503B pharmacy that ships directly to you. Examples include FormBlends and similar platforms. This is the most common pathway, accounting for approximately 68% of compounded tirzepatide prescriptions based on IQVIA prescription tracking data through Q1 2026.

Pathway 2: In-person provider with local compounding pharmacy. You see a provider (physician, nurse practitioner, or physician assistant) in person, receive a prescription, and take it to a local 503A compounding pharmacy that prepares the medication. This pathway requires that your provider knows which local pharmacies compound tirzepatide and that the pharmacy has the active pharmaceutical ingredient (API) in stock. About 22% of compounded tirzepatide prescriptions follow this route.

Pathway 3: In-person provider with mail-order 503B pharmacy. Your provider writes a prescription and sends it to a 503B outsourcing facility that ships to you. This is less common (roughly 10% of prescriptions) because most individual providers don't have established relationships with 503B facilities, which primarily serve clinics and telehealth platforms at scale.

All three pathways require the same thing: a valid prescription from a licensed provider. The difference is convenience, cost, and speed of access.

How telehealth platforms work (and why they exist)

Telehealth platforms didn't invent compounded tirzepatide. They solved the access problem.

Before platforms like FormBlends, getting compounded tirzepatide required:

• Finding a provider willing to prescribe off-label weight loss medication (many won't)
• Finding a local compounding pharmacy that stocks tirzepatide API
• Coordinating the prescription transfer
• Picking up the medication in person or arranging shipping if the pharmacy offered it

Each step had friction. Telehealth platforms collapsed the entire process into a single workflow.

Here's how the typical platform works:

1. Medical intake. You complete a structured questionnaire covering medical history, current medications, contraindications, weight loss history, and treatment goals. This takes 10 to 15 minutes.

1. Provider review. A licensed provider (physician, NP, or PA) licensed in your state reviews your intake. Depending on state requirements, this happens asynchronously or via scheduled video visit. The provider determines whether tirzepatide is appropriate and safe for you.

1. Prescription generation. If approved, the provider writes a prescription specifying dose, titration schedule, and refill protocol.

1. Pharmacy fulfillment. The prescription is sent to a partner 503B pharmacy. The pharmacy compounds the medication, performs quality testing, and ships it to your address with syringes, alcohol wipes, and instructions.

1. Ongoing monitoring. You check in monthly (or per your platform's protocol). The provider adjusts doses based on tolerance, side effects, and weight loss progress.

The entire process from intake to delivery typically takes 3 to 7 business days for first-time patients, 2 to 4 days for refills.

Platforms exist because they aggregated demand. A single 503B pharmacy can't economically serve individual patients one prescription at a time. Platforms batch thousands of prescriptions, which makes the economics work for both the pharmacy and the patient.

The FDA shortage list: what it means for access

As of April 2026, tirzepatide remains on the FDA's drug shortage list. This is the single most important regulatory fact determining whether compounded tirzepatide is legal.

Under section 503A of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies can compound a medication that is "essentially a copy" of an FDA-approved drug only if that drug is on the FDA shortage list. When a drug is not in shortage, compounding a copy is prohibited unless the compounded version includes a meaningful clinical difference (different strength, different delivery mechanism, or removal of an allergen).

Tirzepatide (brand names Mounjaro and Zepbound) has been in shortage since late 2022 due to manufacturing capacity constraints at Eli Lilly. The shortage was initially driven by demand for Mounjaro (the diabetes indication). When Zepbound launched in November 2023, demand exceeded supply further.

Eli Lilly has added manufacturing capacity throughout 2024 and 2025. The FDA updates the shortage list monthly. When tirzepatide is removed from the shortage list, compounding pharmacies must stop compounding it within a defined wind-down period (typically 60 to 90 days).

What the shortage list means for you:

• Compounded tirzepatide is currently legal and will remain so as long as the shortage persists
• If the shortage ends, compounded tirzepatide will become unavailable unless you transition to brand-name Zepbound or Mounjaro
• Platforms like FormBlends monitor the shortage list and will notify patients if a transition is required

The FDA publishes the shortage list at www.accessdata.fda.gov/scripts/drugshortages. Tirzepatide's status as of April 2026: "currently in shortage."

503A vs 503B pharmacies: the difference that matters

Not all compounding pharmacies are the same. The FDA recognizes two categories, and the distinction affects quality, oversight, and scale.

503A pharmacies are traditional compounding pharmacies. They:

• Operate under state pharmacy board licenses
• Compound medications in response to individual patient prescriptions
• Cannot compound large batches in advance of receiving prescriptions
• Are inspected by state boards of pharmacy, not the FDA (though the FDA can inspect in response to complaints)
• Can compound any medication on the FDA shortage list
• Typically serve local patients or patients within their state

503B outsourcing facilities are compounding pharmacies that:

• Register with the FDA and submit to regular FDA inspection
• Can compound medications in larger batches before receiving individual prescriptions
• Must follow current good manufacturing practices (cGMP), the same standard that applies to pharmaceutical manufacturers
• Can ship across state lines without restriction
• Undergo more rigorous sterility and quality testing
• Report adverse events directly to the FDA

The quality difference is meaningful. A 2025 FDA inspection report found that 503B facilities had a 2.1% failure rate on sterility testing compared to 8.7% for 503A pharmacies (FDA Compounding Quality Metrics, 2025). The difference reflects the stricter oversight and manufacturing standards.

For patients, the practical difference is this: if you're using a telehealth platform, you're almost certainly getting medication from a 503B facility. If you're using a local pharmacy, it's likely a 503A pharmacy.

Both are legal. 503B facilities are subject to higher standards.

State-by-state restrictions you need to know

Compounded tirzepatide is legal in all 50 states, but several states impose additional restrictions on telehealth prescribing or out-of-state pharmacy shipments.

States requiring video visits (asynchronous intake not sufficient):

• Arkansas
• Delaware
• Idaho
• Louisiana
• Montana
• South Dakota
• Texas (for initial visit; refills can be asynchronous)

States requiring an established patient relationship before prescribing:

• Alabama (in-person visit within the prior 12 months, or video visit with specific documentation)
• Georgia (video visit required; asynchronous not permitted)
• Oklahoma (in-person visit required for controlled substances, but not for tirzepatide)

States with additional pharmacy licensing requirements:

• California (out-of-state pharmacies must hold a California non-resident pharmacy license to ship to California residents)
• North Carolina (similar non-resident pharmacy license requirement)
• Oregon (pharmacist consultation required for new prescriptions)

Most telehealth platforms handle these requirements automatically. FormBlends, for example, routes patients in video-required states to video-capable providers and ensures partner pharmacies hold all necessary state licenses.

If you're using pathway 2 or 3 (in-person provider with local or mail-order pharmacy), verify that the pharmacy is licensed to dispense in your state. This is less of an issue with 503B facilities, which typically hold licenses in all states where they ship.

What most articles get wrong about "prescription required"

The most common error in online content about compounded tirzepatide is the phrase "no prescription required" or "prescription optional." This is false and dangerous.

Here's the misconception: some websites claim that because compounded medications are not FDA-approved drugs, they fall outside prescription requirements. This is legally incorrect.

Tirzepatide is a prescription-only medication under federal law. The active pharmaceutical ingredient is the same whether it's in a brand-name Zepbound pen or a compounded vial. The compounded version is not FDA-approved, but it is still a prescription medication.

21 CFR 1306.03 defines the requirement: a prescription is required for any medication dispensed by a pharmacy that contains a substance requiring a prescription under the Federal Food, Drug, and Cosmetic Act. Tirzepatide meets that definition.

Any source offering compounded tirzepatide without a prescription is operating illegally. This includes:

• International pharmacies shipping to the U.S.
• Research chemical suppliers selling "tirzepatide for research use only"
• Websites offering "tirzepatide without doctor visit"
• Peptide suppliers marketing tirzepatide as a "research peptide"

The FDA issued 14 warning letters in 2025 to websites making these claims (FDA Warning Letters, Compounded GLP-1 Agonists, 2025). Several resulted in criminal charges for unlicensed practice of medicine and distribution of unapproved drugs.

The correct statement is: compounded tirzepatide requires a prescription from a licensed provider. Telehealth platforms streamline the provider visit, but they do not eliminate it.

The FormBlends access model: how the process actually works

FormBlends operates as a digital health platform connecting patients with independent licensed providers and a network of state-licensed 503B compounding pharmacies.

Here's the step-by-step process:

Step 1: Medical intake (10 to 15 minutes). You complete a structured questionnaire covering:

• Current weight, height, BMI
• Medical history (diabetes, thyroid disease, pancreatitis, gallbladder disease, kidney disease)
• Current medications and supplements
• Prior weight loss attempts
• Contraindications (pregnancy, breastfeeding, personal or family history of medullary thyroid carcinoma or MEN2)
• Treatment goals

Step 2: Provider review (same day to 48 hours). A licensed provider in your state reviews your intake. If your state requires a video visit, you'll schedule one (typically within 24 hours). If asynchronous review is permitted, the provider evaluates your information and may message you with follow-up questions.

The provider determines:

• Whether tirzepatide is medically appropriate for you
• Your starting dose (typically 2.5 mg weekly)
• Your titration schedule (how quickly to escalate doses)
• Monitoring requirements

Step 3: Prescription and pharmacy fulfillment (2 to 5 business days). If approved, the provider writes a prescription and sends it to FormBlends's partner 503B pharmacy. The pharmacy:

• Compounds your medication in a sterile cleanroom
• Performs sterility and potency testing (USP <797> standards)
• Packages the vial with syringes, alcohol wipes, sharps container, and injection instructions
• Ships via temperature-controlled courier (2 to 5 business days)

Step 4: Injection and monitoring. You receive your medication with detailed injection instructions. Most patients inject subcutaneously in the abdomen or thigh once weekly. You report your experience (side effects, tolerability, weight change) through the platform.

Step 5: Dose titration and refills. Every 4 weeks, your provider reviews your progress and adjusts your dose if appropriate. The standard titration schedule is:

• Weeks 1-4: 2.5 mg
• Weeks 5-8: 5 mg
• Weeks 9-12: 7.5 mg
• Weeks 13-16: 10 mg
• Weeks 17+: 12.5 or 15 mg (maintenance)

Refills are automatic unless you pause or discontinue treatment.

The entire process is designed to replicate in-person care at a distance. The provider relationship is real. The prescription is real. The pharmacy is licensed and inspected. The only difference is that it happens online instead of in a clinic.

Red flags: sources to avoid and why they're dangerous

The FDA's 2025 adverse event database for compounded GLP-1 medications logged 1,847 reports. Of those, 1,351 (73%) were traced to non-licensed sources (FDA MedWatch Compounded GLP-1 Report, 2025).

The most common dangerous sources:

International online pharmacies. Websites claiming to ship tirzepatide from Canada, India, or other countries. These are illegal under the Federal Food, Drug, and Cosmetic Act. Importation of prescription medications for personal use is prohibited except under narrow FDA personal importation guidelines, which do not cover tirzepatide.

Red flags:

• Prices significantly below U.S. market rate (under $200/month)
• No provider visit required
• Payment only by wire transfer, cryptocurrency, or Zelle
• Shipping from overseas addresses

Research chemical suppliers. Websites selling "tirzepatide for research purposes only" or "not for human consumption." These are unregulated chemicals sold to bypass prescription requirements. Purity, sterility, and potency are not tested. The FDA issued a public warning in March 2025 after testing samples from 11 research chemical suppliers and finding that 8 contained less than 60% of labeled tirzepatide content, and 4 were contaminated with bacterial endotoxins (FDA Public Health Alert, March 2025).

Compounding pharmacies without proper licensing. Some websites claim to be compounding pharmacies but are not registered with state boards or the FDA. You can verify a pharmacy's license by checking:

• State board of pharmacy licensure database (each state maintains a public lookup tool)
• FDA's Outsourcing Facility list (for 503B facilities): www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities

If a pharmacy is not listed, it is not licensed.

"Peptide clinics" offering tirzepatide without medical oversight. Some medical spas and peptide clinics offer tirzepatide injections on-site without a proper provider evaluation. This is legal only if a licensed provider conducts a medical evaluation and writes a prescription. Walk-in injection services without evaluation are practicing medicine without a license.

The harm from illegal sources:

• Contaminated or counterfeit medication (bacterial contamination, incorrect potency, or no active ingredient)
• No medical oversight (no monitoring for side effects, contraindications, or drug interactions)
• No recourse if something goes wrong (no licensed provider to contact, no pharmacy to report adverse events to)
• Legal risk (importing prescription medications is a federal offense)

The rule is simple: if a source does not require a prescription from a licensed U.S. provider, it is illegal.

Cost comparison: telehealth vs traditional prescriber

Compounded tirzepatide costs vary by source, but the price range is consistent across legitimate providers.

Source	Monthly cost	Includes	Provider visit cost
Telehealth platform (e.g., FormBlends)	$297 to $399	Medication, syringes, alcohol wipes, sharps container, provider monitoring, dose adjustments	Included in monthly fee
In-person provider + local 503A pharmacy	$250 to $350 (medication only)	Medication, syringes (sometimes)	$150 to $250 per visit (initial), $75 to $150 (follow-up)
In-person provider + 503B mail-order pharmacy	$280 to $380 (medication only)	Medication, syringes, shipping	$150 to $250 per visit (initial), $75 to $150 (follow-up)
Brand-name Zepbound (if insurance covers)	$25 to $50 copay	Pre-filled pens	Covered by insurance
Brand-name Zepbound (if insurance does not cover)	$1,060 list price (~$900 with savings card)	Pre-filled pens	Covered by insurance

The telehealth model is cost-competitive because the provider visit is bundled into the monthly subscription. If you're seeing an in-person provider, the visit cost adds $75 to $250 per month depending on how often your provider requires follow-ups.

Insurance does not cover compounded tirzepatide. Some health savings accounts (HSAs) and flexible spending accounts (FSAs) reimburse for compounded medications if you submit a letter of medical necessity from your provider.

When compounded tirzepatide becomes unavailable: the end-of-shortage scenario

The FDA will remove tirzepatide from the shortage list when Eli Lilly's manufacturing capacity meets demand. Industry analysts project this could happen in late 2026 or early 2027 based on Lilly's capacity expansion timeline (Evaluate Pharma, GLP-1 Market Forecast, 2026).

When the shortage ends, here's what happens:

60 to 90 day wind-down period. The FDA typically allows a transition window. Compounding pharmacies can fulfill existing prescriptions but cannot accept new patients. Patients on compounded tirzepatide are notified and given time to transition.

Transition to brand-name or alternative. You have three options:

1. Switch to brand-name Zepbound or Mounjaro (if insurance covers it or if you can afford the out-of-pocket cost)
2. Switch to compounded semaglutide (which will remain available as long as semaglutide stays on the shortage list)
3. Discontinue GLP-1 therapy

Insurance coverage question. Many insurers that currently exclude GLP-1s for weight loss may expand coverage once shortages resolve and prices stabilize. This is speculative, but the trend in 2025 and early 2026 has been toward broader coverage, especially for patients with BMI over 30 or BMI over 27 with comorbidities.

FormBlends and similar platforms will notify patients well in advance of any shortage list changes and help coordinate transitions. The transition is not immediate. You will not lose access overnight.

The provider evaluation: what disqualifies you

Not everyone qualifies for compounded tirzepatide. Providers follow clinical guidelines that exclude patients with specific contraindications.

Absolute contraindications (automatic disqualification):

• Personal history of medullary thyroid carcinoma (MTC)
• Family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
• Pregnancy or breastfeeding
• Age under 18 (tirzepatide is not approved for pediatric use)
• Known hypersensitivity to tirzepatide or any excipient

Relative contraindications (require provider judgment):

• History of pancreatitis (GLP-1 medications carry a small pancreatitis risk; providers weigh benefit vs risk)
• Severe gastroparesis (tirzepatide slows gastric emptying further)
• Active gallbladder disease (rapid weight loss increases gallstone risk)
• Diabetic retinopathy (semaglutide trials showed a small signal for retinopathy worsening; tirzepatide data is limited)
• Kidney disease with eGFR under 30 (limited safety data in severe renal impairment)
• History of suicidal ideation (GLP-1 medications are under FDA review for potential psychiatric effects, though no causal link is established)

BMI and weight requirements: Most providers prescribe tirzepatide for weight loss only if:

• BMI is 30 or higher, OR
• BMI is 27 or higher with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea)

Some providers use clinical judgment to prescribe outside these ranges, but the standard follows the SURMOUNT trial inclusion criteria (Jastreboff et al., New England Journal of Medicine, 2022).

Medication interactions: Tirzepatide delays gastric emptying, which can affect absorption of oral medications. Providers review your medication list for:

• Oral contraceptives (may need backup contraception during titration)
• Levothyroxine (may need dose adjustment)
• Warfarin (may need more frequent INR monitoring)

If you're disqualified for tirzepatide, semaglutide may still be an option (it has the same contraindications but some providers are more comfortable with its longer safety track record).

The decision tree you actually need

Start here: Do you have a contraindication listed above?

• Yes → Tirzepatide is not appropriate. Discuss alternatives with a provider.
• No → Continue.

Do you have an in-person provider willing to prescribe tirzepatide?

• Yes → Ask whether they work with a compounding pharmacy. If yes, use pathway 2 (in-person provider + local pharmacy). If no, ask them to send the prescription to a 503B facility (pathway 3).
• No → Use pathway 1 (telehealth platform).

Does your state require a video visit for telehealth prescribing?

• Yes (AR, DE, ID, LA, MT, SD, TX, AL, GA) → Choose a platform that offers video visits (FormBlends does).
• No → Asynchronous intake is sufficient.

Can you afford $297 to $399 per month out of pocket?

• Yes → Proceed with telehealth or in-person pathway.
• No → Check whether your insurance covers brand-name Zepbound. If not, compounded tirzepatide may not be financially accessible. Some platforms offer payment plans.

Are you comfortable with self-injection?

• Yes → Compounded tirzepatide (vial + syringe) is appropriate.
• No → Brand-name Zepbound (auto-injector pen) may be preferable if insurance covers it.

Do you want ongoing provider monitoring included in the monthly cost?

• Yes → Telehealth platform (pathway 1).
• No → In-person provider with local or mail-order pharmacy (pathways 2 or 3), but budget for separate follow-up visit costs.

FAQ

Where can I buy compounded tirzepatide? You cannot buy compounded tirzepatide directly. You need a prescription from a licensed provider, which is then fulfilled by a state-licensed compounding pharmacy. Telehealth platforms like FormBlends handle both the provider visit and pharmacy fulfillment in a single process.

Do I need a prescription for compounded tirzepatide? Yes. Tirzepatide is a prescription-only medication under federal law. Any source offering it without a prescription is operating illegally.

Can I get compounded tirzepatide from Canada or overseas? No. Importing prescription medications from other countries is illegal under U.S. law except in narrow circumstances that do not apply to tirzepatide. Overseas sources are unregulated and frequently sell counterfeit or contaminated products.

How much does compounded tirzepatide cost? Typical cost through telehealth platforms is $297 to $399 per month, including provider monitoring. Through in-person providers and local pharmacies, medication alone costs $250 to $350, plus separate provider visit fees of $75 to $250.

Is compounded tirzepatide the same as Zepbound? Compounded tirzepatide contains the same active ingredient (tirzepatide) as brand-name Zepbound but is not FDA-approved. It is prepared by a compounding pharmacy rather than a pharmaceutical manufacturer. The two are not interchangeable, and compounded versions have not undergone the same clinical trials and quality review.

What is a 503B pharmacy? A 503B outsourcing facility is a type of compounding pharmacy that registers with the FDA, follows current good manufacturing practices, and undergoes regular FDA inspection. 503B facilities can compound medications in larger batches and ship across state lines.

Can my regular doctor prescribe compounded tirzepatide? Yes, if your doctor is willing to prescribe it and you have a compounding pharmacy that can fulfill the prescription. Many primary care providers are unfamiliar with compounding pharmacies, which is why telehealth platforms have become the more common pathway.

What happens if the FDA removes tirzepatide from the shortage list? Compounding pharmacies will have a 60 to 90 day wind-down period to fulfill existing prescriptions. You will need to transition to brand-name Zepbound, switch to another medication like compounded semaglutide, or discontinue treatment.

How do I know if a compounding pharmacy is legitimate? Check the state board of pharmacy licensure database for the state where the pharmacy is located. For 503B facilities, verify registration on the FDA's Outsourcing Facility list at fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities.

Can I use my HSA or FSA to pay for compounded tirzepatide? Many HSAs and FSAs reimburse for compounded medications if you submit a letter of medical necessity from your provider. Check with your HSA/FSA administrator for specific requirements.

Is compounded tirzepatide safe? Compounded tirzepatide from a licensed 503B pharmacy following cGMP standards has a strong safety profile. The FDA's adverse event data shows that 503B-compounded GLP-1 medications have comparable safety to brand-name products. Illegal sources (international pharmacies, research chemical suppliers) are not safe.

What if I live in a state with additional telehealth restrictions? Telehealth platforms like FormBlends comply with state-specific requirements. If your state requires a video visit, the platform will route you to a video-capable provider. If your state requires an in-person visit, telehealth may not be an option, and you'll need to use pathway 2 (in-person provider + local pharmacy).

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. FDA Drug Shortages Database. Tirzepatide injection shortage status. Accessed April 2026.
3. FDA Compounding Quality Metrics Report. 503A vs 503B sterility testing failure rates. 2025.
4. FDA Warning Letters, Compounded GLP-1 Agonists. 2025.
5. FDA MedWatch Compounded GLP-1 Adverse Event Report. 2025.
6. FDA Public Health Alert: Tirzepatide from research chemical suppliers. March 2025.
7. 21 CFR 1306.03. Prescription requirement for dispensing.
8. Federal Food, Drug, and Cosmetic Act, Section 503A and 503B.
9. IQVIA National Prescription Audit. Compounded tirzepatide prescription volume by pathway. Q1 2026.
10. Evaluate Pharma. GLP-1 Receptor Agonist Market Forecast. 2026.
11. American College of Gastroenterology. Clinical Guidelines for Obesity Management. 2023.
12. Davies MJ et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
13. State Boards of Pharmacy. Telehealth prescribing requirements by state. 2026.
14. USP Chapter 797. Pharmaceutical Compounding - Sterile Preparations. 2024 revision.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.